Clinical Trial

Metabolic Flexibility to Predict Lifestyle Interventions Outcomes

Study acronym: MEPHISTO
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2024 (before its estimated December 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
Weight loss is a cornerstone of diabetes (T2D) management, yet in clinical practice, its delivery is limited by its perceived burdensome nature and variability in response. Personalization of the interventions to increase their success rate is an unmet clinical need. The proposed project MEPHISTO (Whole body and gut microbiome metabolic flexibility to predict lifestyle intervention outcomes) would aim to identify predictive features related to successful weight loss upon sequential exercise and diet intervention in people living with obesity. To this end, the study aims to conduct a clinical trial where the investigators would implement state-of-the-art physiological phenotyping of metabolic flexibility at the whole-body level and at the level of the gut in persons with obesity before and after exercise and diet + exercise intervention to identify predictive signatures of successful weight loss
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-22.
Trial Details
NCT Number NCT06329349
Lead Sponsor Charles University, Czech Republic
Collaborators: Ministry of Health, Czech Republic, EXCELES LX22NPO5104, CarDia
Conditions Obesity
Enrollment 30 participants
Start Date 2024-01-02
Primary Completion 2025-12-12 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-28